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Various natural products, drugs and active pharmaceutical 
ingredients possess heterocyclic rings which are primarily 
responsible for their biological activity.1 Benzodiazepines which 
contain two nitrogens in an arene-fused seven membered ring are 
one of the highly privileged heterocyclic systems.2 These 
compounds exhibit diverse biological activities and are among 
the most commonly prescribed anti-depressants (Figure 1).3 Ever 
since the first benzodiazepine drug chlordiazepoxide has been 
reported in 1955 by Sternbach,4 this class of compounds began 
receiving increasing attention. This resulted in the development 
of numerous drugs containing benzodiazepines.5 The biological 
significance of benzodiazepine skeleton also prompted 
development of different synthetic routes from various 
precursors. These include reaction of o-phenylenediamine with 
different bielectrophiles,6 one pot conversion of nitroarenes using 
bimetallic nanoparticles,7 Au(I)-NHC-catalyzed synthesis from 
N-substituted o-phenylenediamines and terminal alkynes8 tc.9 
Owing to the importance of nitro group in biologically active 
compounds,10 and particularly nitrobenzodiazepines (NBDZs) as 
hypnotic and sedative drugs,11 synthesis of novel NBDZs, in 
which the nitro group is attached to the 7-membered dinitrogen 
heterocycle rather than to the aromatic ring, via one pot cascade 
reactions from readily available starting materials ppeared an 
attractive objective.    
 
Figure 1. Bioactive molecules containing benzazepine 
skeleton 
  
While one of the substrates for the synthesis of the NBDZs 
appeared to be 1,4-binucleophilic o-phenylenediamine, a 1,3-
bielectrophilic nitroalkene derivative emerged as the other 
substrate. Over the years, we, Chen and others have been actively 
working on the synthetic applications of nitroallylic acetates, 
derived from Morita-Baylis-Hillman (MBH) reactions of 
nitroalkenes with activated carbonyl compounds.12 Numerous 
fused and functionalized heterocycles including furans,13 
pyrans,14 pyrroles,15 dihydropyridopyrimidines,16 imidazoles,17 
imidazopyridines,18 benzimidazothiazines,19 picolinate,20 
piperidines,21 benzoxacinones,22 thiopyranoindoles23 etc have 
been synthesized from such nitroalkene derived MBH acetates by 
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A [4+3] annulation of o-phenylenediamines with primary nitroallylic acetates affords 
nitrobenzodiazepines (NBDZs) in good to excellent yield. The reaction which proceeds in 
MeOH at room temperature in the absence of any baseor catalyst involves a cascade SN2 N-
nitroallylation-intramolecular aza-Michael addition sequence. In the case of mono-N-arylated o-
phenylenediamines and o-aminobenzamides, the reaction stops at the SN2 stage affording 
nitroallylic amines. On the other hand, reaction of o-aminobenzamides with secondary 
nitroallylic acetates delivers SN2’ products. Formation of stable SN2 and SN2’ products provides 
insights into the reactivity of primary and secondary nitroallylic acetates and also the mechanism 
of formation of nitrobenzodiazepines. 
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us and other research groups.  However, to the best of our 
knowledge, there is no report on the synthesis of benzodiazepines 
from MBH acetates as bielectrophiles through a [4+3] annulation 
strategy. Herein, we report the first direct synthesis of NBDZs 
from o-phenylenediamines and nitroallylic acetates through a 
cascade N-alkylation-intramolecular aza-Michael addition. Also 
included in this report are the results of our studies on the 
reactivity of related 1,4- and 1,5-binucleophiles towards MBH 
acetates. 
 
2. Results and Discussion 
   Optimization studies by taking the bielectrophilic MBH acetate 
1a and the binucleophilic o-phenylediamine 2a as the model 
substrates revealed that the reaction works smoothly in MeOH at 
room temperature as in the case of our imidazopyridine synthesis 
from aminopyridine and MBH acetate.18 There was no 
requirement of any base or catalyst and the desired compound 3a 
was formed in 78% yield as a single diastereomer in a short 
reaction time of 4 h (Table 1). The trans stereochemistry between 
the furyl group and the nitro group in 3a was evident from a J
value of 9.4 Hz for the coupling between the two aliphatic vicinal 
methine protons. 
 
Table 1. Optimization of reaction conditions 
 
entry Solvent time (h) yield (%)a 
1 MeOH 4 78 
2 EtOH 7 71 
3 MeOH : H2O
b 5 26 
4 MeCN 9 13 
5 THF 8 23 
6 DMF 12 traces 
7 DCM 6 16 
aAfter silica gel column chromatography. b 1:1 Ratio 
   The scope of the reaction was then investigated with a diverse 
array of MBH acetates (Table 2). There was no appreciable 
substituent effect on the yield which remained in the range of 68-
86%. For instance, MBH acetates 1a and 1k bearing heteroaryl 
groups afforded the diazepines 3a and 3k in 78% and 68% yields, 
respectively. Substrates bearing electroneutral aryl nd weakly 
activated aryl 1b and 1c, respectively, provided the 
corresponding diazepines 3b and 3c in comparable yields (79-
80%). Strongly activated aryls with single and multiple electron 
donating groups 1d-f also helped maintain high yields (80-84%) 
of the products 3d-f. While weakly and strongly electron 
withdrawing groups on the aryl ring of the substrates 1g-i and 1j, 
respectively, did not influence the yields of the diazepines 3g-j  to 
any appreciable extent (75-86%), ortho-substitution did affect the 
diastereoselectivity as in the case of 3h and 3j. 
Table 2. Synthesis of benzodiazepines from o-phenylene-
diamines and MBH acetatesa 
 
aYield after silica gel column chromatography, dr was determined by 1H 
NMR of the crude reaction mixture.   
Subsequently, the reaction of substituted o-phenylenediamines 
2b-c with a representative MBH acetate 1a led to the formation 
of an inseparable mixture of regioisomers 4ab+5ab and 4ac+5ac, 
respectively, in ~ 1:1 ratio (Scheme 1). However, the products 
were isolated as single diastereomers in high yields (76-84%). 
 Scheme 1. Benzodiazepines from substituted o-phenylenediamines and 
MBH acetate
 
The effect of substituent on the amine nitrogen was then 
evaluated using 2d as the representative binucleophile (Table 3). 
This enabled us to compare the reactivity of primary nd 
secondary aromatic amines towards MBH acetate 1. Though not 
 3 
unexpected, we isolated only the SN2 products 7 in most cases 
instead of diazepines 6. The intramolecular cyclization has taken 
place only in the case of MBH acetate 1h with an ortho-
substituent on the aromatic ring which afforded diazepine 6h in 
good yield (72%) and diastereoselectivity (88:12). However, this 
shed more light into the mechanism (vide infra) that e first step 
in the reaction would be SN2 rather than SN2’. The nitroallylic 
amines bearing weakly and strongly electron donating aryl 
groups 7a, 7c, 7d, 7f, 7l and 7n were formed in higher yields (74-
85%) as compared to those bearing weakly and strongly electron 
withdrawing aryl groups 7g and 7j as well as the one with a fused 
aryl group 7m (70-72%). The intramolecular cyclization of the 
above SN2 products, including 7n bearing an o-substituent, to 
diazepines 6 has not taken place upon heating24 (conventional 
and microwave) and/or in the presence of a variety of bases such 
as DABCO, DBU, TMG, NaH, Cs2CO3, KOH and LiO
tBu. 
Unfortunately, strong bases and/or extreme conditions caused 
decomposition of the substrates. 
Table 3. Nitroallylation of N-phenyl-o-phenylenediamine 
with MBH acetatesa 
  
aYield after silica gel column chromatography. 
As briefly stated earlier, the relative stereochemistry of 
compounds 3-6 appeared to be trans from the J value of 9-10 Hz 
for the two aliphatic vicinal methine protons. However, a 
dihedral angle of 68.7° for the ArC-C-C-N chain in the X-ray 
structure of a representative compound 3g suggested that the aryl 
and nitro groups have a synclinal relationship (See th  SI).  
In view of the isolation of SN2 products 7, the first step in the 
formation of NBDZs 3 is confirmed to be the SN2 reaction of o-
phenylenediamine 2 with MBH acetate 1 (Scheme 2). The 
reaction proceeds further in the case of N-unsubstituted o-
phenylenediamines 2a-c in an intramolecular aza-Michael 
fashion to afford NBDZs 3. However, when the nucleophilicity 
of one of the amino groups is curtailed, as in the case of 2d, the 
reaction stops at the SN2 stage. Yet another reason for the 
reluctance of most of the SN2 products 7 to undergo the 
intramolecular aza-Michael addition is a probable 1,2-allylic 
strain (A1,2) between the two aryl groups in the transition state. 
 
Scheme 2. Proposed mechanism for the formation of nitro-
benzodiazepines 
  
Under the above conditions, a 1,2-amino alcohol such as 
phenyl alaninol 2e participated in the SN2 reaction with MBH 
acetate 1a (1a:2e  in 2:1 ratio) displacing the acetate group twice 
to generate compound 8 (Scheme 3). This double nitroallylation 
of the amino group in 2e provides novel bis-nitroallylic tertiary 
amines confirming the greater reactivity of aliphatic mines. 
 
Scheme 3. Double nitroallylation of phenylalaninol with 
MBH acetate 
 
Having obtained  NBDZs and their precursors depending upon 
the nature of the binucleophile, we intended to investigate the 
bielectrophilic nature of MBH acetate 1 with a binucleophile 
bearing strongly nucleophilic amino group and a weakly 
nucleophilic amido group. With this objective, we have chosen 2-
aminobenzamide 2f whose ability to react as a 1,5-binucleophile 
with electrophiles through both amine-N and amide-N in the 
formation of 6-membered rings (quinoxalines) is  documented in 
the literature.25 However, our experimentation with MBH 
acetates possessing electronically different aryl groups confirmed 
that the reaction stops at the SN2 stage affording products 9 under 
these conditions (Table 4). This is attributable to the poor 
nucleophilicity of the amide group as well as entropically 
disfavored formation of an 8-membered ring. No appreciable 
substituent effect was observed on the yield of N-nitroallylation 
(SN2) product as those with electron rich aryl groups 9d and 9l 
and those with electron poor aryl groups 9g and 9j were formed 
in excellent yield (80-90%). The naphthyl derivative 9m was also 
formed in high yield (77%). Attempted cyclization of compounds 
9 to 8-membered ring by heating and/or using different bases did 
not provide the desired results. But nevertheless, the multi-
functional SN2 products were formed in excellent yield (77-90%).
 
Tetrahedron 4
Table 4. Nitroallylation of 2-aminobenzamide with MBH 
acetatesa 
 
aYield after silica gel column chromatography. 
   At this juncture, we wished to examine the reactivity of MBH 
acetate 10, which was derived from nitroalkene and 
ethylglyoxylate, towards 2-aminobenzamide 2f (Scheme 4). As 
expected, based on the reported reactivity of secondary acetate 
10,12 it reacted in an SN2’ fashion, unlike the primary acetate 1 
and provided product 11. Two possible modes of intramolecular 
cyclization of compound 11, viz 7-exo-trig and 8-endo-trig did 
not take place under a variety of thermal, including microwave, 
and/or base assisted conditions. Attempted reaction of MBH 
acetate 10 with o-phenylenediamine 2a under these conditions 
and at 0°C as well as in other solvents such as EtOH, THF and 
DCM resulted in complex mixtures.26 
 
Scheme 4. Reaction of 2-aminobenzamide with secondary 
MBH acetate 
 
In order to examine the applicability of the above experimental 
conditions to other MBH acetates, ethyl acrylate derived MBH 
acetate 12 was treated with o-phenylenediamine 2a (Scheme 5). 
The reaction afforded  the expected diazepine 13, though only in 
35% yield and in long reaction time of 48 h.27 This confirmed  
that our base and catalyst free method is applicable for the 
synthesis of benzo-1,4-diazepines, not only from MBH acetates 
derived from nitroalkenes but other activated alkenes as well. 
 
Scheme 5. Reaction of ethyl acrylate derived MBH acetate 
with o-phenylenediamine 
3. Conclusion 
   In conclusion, we have successfully demonstrated  simple 
and efficient way to synthesize nitrobenzodiazepines from MBH 
acetates of nitroalkenes and o-phenylenediamine without using 
any base or catalyst. The products are formed in good to 
excellent yields and excellent diastereoselectivity. The 
mechanism involves SN2 N-nitroallylation followed by an 
intramolecular aza-Michael addition which was confirmed by 
isolation and characterization of several N-nitroallyl ted 
intermediates in the case of diamines/aminoamides with different 
nucleophilicities. The N-nitroallylated compounds in turn are 
multi-functional species bearing a conjugated  nitroalkene, allylic 
amine and a secondary amine or a primary carboxamide oiety. 
 
General Experimental Details.  
The melting points recorded are uncorrected. NMR spectra 
(1H, 1H decoupled 13C and 1H-1H COSY) were recorded with 
TMS as the internal standard. The coupling constant (J values) 
are given in Hz. High resolution mass spectra were record d 
under ESI Q-TOF conditions. X-ray data were collected on a 
diffractometer equipped with graphite monochromated Mo Kα 
radiation. The structure was solved by direct methods shelxs97 
and refined by full-matrix least squares against F2 using shelxl97 
software. Amines and aminoamides 2a-f were commercially 
available. MBH acetates 1,28 1029  and 1230 were prepared by 
literature methods. The identity and purity of substrates 1, 10 and 
12 were in general confirmed by comparison of their physical 
and spectroscopic data with those reported in the lierature.28-30 
General procedure for the reaction of MBH acetate 1 with 
amines 2a-e.  
To a stirred solution of MBH acetate 1 (0.5 mmol) in 
methanol (5 mL) at room temperature was added amino 
compound 2 (0.5 mmol). The reaction mixture was stirred till 
complete consumption of the starting materials (monitored by 
TLC). The solvent was evaporated in vacuo and the crude residue 
was purified by silica gel column chromatography (10-20% EA / 
pet ether). 
2-(Furan-2-yl)-3-nitro-2,3,4,5-tetrahydro-1H-benzo-
[b][1,4]diazepine (3a). Yellow solid; Yield 101 mg, 78%, dr 
>95:05;  mp 90 oC; IR (film, cm-1) 3394 (br m), 2925 (w), 1601 
(m), 1554 (s), 1506 (m), 1457 (m), 1266 (m), 1014 (m), 745 (vs); 
1H NMR (CDCl3, 400 MHz) δ 7.43 (dd, J = 1.7, 0.6 Hz, 1H), 
6.71-6.79 (m, 2H), 6.63 (td, J = 7.5, 1.7 Hz, 2H), 6.33-6.37 (m, 
2H), 5.54 (d, J = 9.4 Hz, 1H), 5.08 (ddd, J = 9.4, 4.4, 1.9 Hz, 
1H), 4.31 (dd, J = 15.0, 4.4 Hz, 1H), 3.76 (dd, J = 15.0, 1.9 Hz, 
1H), 3.54 (br s, 2H); 13C NMR (CDCl3, 100 MHz) δ 150.9, 143.2, 
137.3, 136.6, 121.8, 121.1, 119.1, 118.6, 110.8, 10.7, 87.1, 55.3, 
48.5; HRMS (ES+, Ar) calcd for C13H13N3O3Na (MNa
+) 
282.0849, found 282.0850. 
3-Nitro-2-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-
diazepine (3b). Yellow sticky solid; Yield 108 mg, 80%, dr 
91:09; Major isomer (minor isomer could not be isolated in pure 
form): mp 80 oC; IR (film, cm-1) 3392 (br s), 3053 (w), 2917 (w), 
1599 (s), 1544 (vs), 1505 (m), 1458 (m), 1352 (m), 1314 (s), 
1266 (m), 1254 (m), 739 (vs); 1H NMR (CDCl3, 400 MHz) δ 
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7.39-7.47 (m, 5H), 6.83 (td, J = 7.6, 1.3 Hz, 1H), 6.77 (td, J = 
7.6, 1.3 Hz, 1H), 6.69 ( dd, J = 7.6, 1.3 Hz, 1H), 6.59 (dd, J = 
7.6, 1.3 Hz, 1H), 5.23 (d, J = 9.7 Hz, 1H), 4.97 (ddd, J = 9.7, 4.3, 
2.9 Hz, 1H), 4.33 (dd, J = 14.6, 4.3 Hz, 1H), 3.77 (br s, 1H), 3.66 
(dd, J = 14.6, 2.9 Hz, 1H), 3.38 (br s, 1H); 13C NMR (CDCl3, 100 
MHz) δ 139.0, 137.6, 137.5, 129.5, 129.3, 127.5, 121.9, 121.4, 
119.4, 119.1, 90.6, 62.6, 49.3; HRMS (ES+, Ar) calcd for 
C15H15N3O2Na (MNa
+) 292.1056, found 292.1058. 
3-Nitro-2-p-tolyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-
diazepine (3c). Yellow solid; Yield 112 mg, 79%, dr >95:5; mp 
146 oC; IR (film, cm-1) 3366 (br m), 2917 (w), 1598 (m), 1536  
(m), 1505 (m), 1462 (s), 1342 (m), 1311 (s), 1251 (vs), 1274 (w), 
1180 (w), 1024 (m), 835 (w), 751 (s); 1H NMR (CDCl3, 400 
MHz) δ 7.33 (d, J = 7.5 Hz, 2H), 7.21 (d, J = 7.5 Hz, 2H), 6.82 
(td, J = 7.6, 1.5 Hz, 1H), 6.76 (td, J = 7.6, 1.5 Hz, 1H), 6.71 (dd, 
J = 7.6, 1.5 Hz, 1H), 6.59 (dd, J = 7.6, 1.5 Hz, 1H), 5.14 (d, J = 
9.7 Hz, 1H), 4.97 (ddd, J = 9.7, 4.3, 3.3 Hz, 1H), 4.31 (dd, J = 
14.6, 4.3 Hz, 1H), 3.66 (dd, J = 14.6, 3.3 Hz, 1H), 3.40 (br s, 
2H), 2.36 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 139.1, 137.6, 
137.5, 136.0, 130.0, 127.4, 121.8, 121.3, 119.3, 119.0, 90.6, 62.3, 
49.3, 21.3; HRMS (ES+, Ar) calcd for C16H17N3O2Na (MNa
+) 
306.1213, found 306.1210.  
2-(4-Methoxyphenyl)-3-nitro-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepine (3d). Yellow solid; Yield 126 mg, 84%, 
dr >95:5; mp 158 oC; IR (film, cm-1) 3381 (br s), 2916 (w), 1600 
(m), 1543 (s), 1514 (s), 1461 (s), 1354 (m), 1315 (s), 1251 (vs), 
1179 (m), 1029 (m), 834 (s), 750 (vs); 1H NMR (CDCl3, 400 
MHz) δ 7.37 (td, J = 8.7, 1.9 Hz, 2H), 6.93, (td, J = 8.7, 1.9 Hz, 
2H), 6.74 (dt, J = 7.5, 1.5 Hz, 1H), 6.79 (dt, J = 7.5, 1.5 Hz, 1H), 
6.69 (dd, J = 7.5, 1.5 Hz, 1H), 5.59 (dd, J = 7.5, 1.5 Hz, 1H), 
5.13 (d, J = 9.8 Hz, 1H), 4.89 (dt, J = 9.8, 2.6 Hz, 1H), 4.28 (dd, 
J = 14.4, 2.6 Hz, 1H), 3.81 (s, 3H), 3.77 (br s, 1H), 3.64 (dd, J = 
14.4, 2.6 Hz, 1H), 3.32 (br s, 1H); 13C NMR (CDCl3, 100 MHz) δ 
160.1, 137.7, 137.5, 131.0, 128.7, 121.8, 121.4, 119.3, 119.1, 
114.7, 90.8, 62.1, 55.5, 49.3; HRMS (ES+, Ar) calcd for 
C16H17N3O3Na (MNa
+) 322.1162, found 322.1162.  
2-(3,4-Dimethoxyphenyl)-3-nitro-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepine (3e). Yellow solid; Yield 135 mg, 82%, 
dr >95:5; mp 175 oC; IR (film, cm-1) 3387 (br m), 2912 (w), 1611 
(m), 1600 (m), 1543 (vs), 1514 (s), 1460 (m), 1353 (m), 1315 (s), 
1252 (vs), 1179 (m), 1031 (m), 833 (m), 750 (s); 1H NMR 
(CDCl3, 400 MHz) δ 6.97 (dd, J = 8.2, 2.0 Hz, 1H), 6.94 (d, J = 
2.0 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.82 (td, J = 7.5, 1.6 Hz, 
1H), 6.76 (td, J = 7.5, 1.6 Hz, 1H), 6.69 (dd, J = 7.5, 1.6 Hz, 1H), 
6.62 (dd, J = 7.5, 1.6 Hz, 1H), 5.11 (d, J = 9.7 Hz, 1H), 4.92 (dt, 
J = 9.7, 3.5 Hz, 1H), 4.26 (br d, J = 13.9 Hz, 1H), 3.89 (s, 3H), 
3.88 (s, 3H), 3.78 (br s, 1H), 3.62 (br d, J = 13.9 Hz, 1H), 3.37 
(br s, 1H); 13C NMR (CDCl3, 100 MHz) δ 149.7, 149.6, 137.7, 
137.6, 131.4, 122.0, 121.5, 119.9, 119.5, 119.2, 111.6, 110.3, 
90.8, 62.5, 56.2, 56.1, 49.4; HRMS (ES+, Ar) calcd for 
C17H19N3O4Na (MNa
+) 352.1268, found 352.1268.  
2-(Benzo[d][1,3]dioxol-5-yl)-3-nitro-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepine (3f). Yellow solid; Yield 125 mg, 80%, 
dr >95:5; mp 129 oC; IR (film, cm-1) 3382 (br s), 2903 (w), 1600 
(m), 1544 (vs), 1505 (m), 1353 (w), 1314 (m), 1249 (vs), 1089 
(m), 1038 (s), 931 (m), 749 (s); 1H NMR (CDCl3, 400 MHz) δ 
6.92 (d, J = 1.7 Hz, 1H), 6.89 (dd, J = 7.9, 1.7 Hz, 1H), 6.80 (d, J 
= 7.9 Hz, 1H), 6.78 (td, J = 7.6, 1.5 Hz, 1H), 6.76 (td, J = 7.6, 1.5 
Hz, 1H), 6.68 (dd, J = 7.6, 1.5 Hz, 1H), 6.59 (dd, J = 7.6, 1.5 Hz, 
1H), 5.98 (s, 2H), 5.10 (d, J = 9.7 Hz, 1H), 4.89 (ddd, J = 9.7, 
4.3, 2.9 Hz, 1H), 4.27 (dd, J = 14.6, 4.3 Hz, 1H), 3.62 (dd, J = 
14.6, 2.9 Hz, 1H), 3.30 (br s, 2H); 13C NMR (CDCl3, 100 MHz) δ 
148.5, 148.3, 137.6, 137.5, 132.7, 122.0, 121.5, 121.3, 119.4, 
119.2, 108.9, 107.6, 101.6, 90.8, 62.5, 49.3; HRMS (E +, Ar) 
calcd for C16H15N3O4Na (MNa
+) 336.0955, found 336.0964.  
2-(4-Chlorophenyl)-3-nitro-2,3,4,5-tetrahydro-1H-benzo-
[b][1,4]diazepine (3g). Yellow solid; Yield 123 mg, 81%, dr 
>95:5; mp 164 oC; IR (film, cm-1) 3389 (br s), 3056 (w), 2916 
(w), 1599 (s), 1543 (vs), 1505 (s), 1492 (s), 1459 (s), 1353 (s), 
1315 (s),   1091 (s), 828 (s), 748 (vs); 1H NMR (CDCl3, 400 
MHz) δ 7.35-7.45 (m, 4H), 6.83 (dt, J = 7.6, 1.4 Hz, 1H), 6.77 
(dt, J = 7.6, 1.4 Hz, 1H), 6.69 (dd, J = 7.6, 1.4 Hz, 1H), 6.59 (dd, 
J = 7.6, 1.4 Hz, 1H), 5.19 (d, J = 9.7 Hz, 1H), 4.87 (ddd, J = 9.7, 
4.3, 3.0 Hz, 1H), 4.31 (dd, J = 14.6, 4.3 Hz, 1H), 3.67 (dd, J = 
14.6, 3.0 Hz, 1H), 3.28 (br s, 1H); 13C NMR (CDCl3, 100 MHz) δ 
137.5, 137.4, 137.3, 135.1, 129.7, 128.9, 122.1, 121.4, 119.4, 
119.0, 90.5, 61.9, 49.3; HRMS (ES+, Ar) calcd for 
C15H14ClN3O2Na (MNa
+) 326.0667, found 326.0668; Selected X-
ray data (CCDC 1941084): C15H14ClN3O2, M=303.74, 
Monoclinic, space group P2(1)/n, a = 10.060(3) Å, b = 15.488(4) 
Å, c = 10.075(3) Å, α = 90°, β = 118.231(4)°, γ = 90°, 
V=1383.0(7) Å3, Z= 4, Dx = 1.459 Mg/m3, F(000)= 632, λ = 
0.71073 Å, µ = 0.284 mm-1, total/unique= 9917/ 2462 [R(int) = 
0.0671], T=100(2) K, θ range= θmax = 25.29°, θmin = 4.16°, 
final R[I>2σ(I)]: R1 = 0.0386, wR2 = 0.1017, R(all data): R1 = 
0.0425, wR2 = 0.1054. 
2-(2-Chlorophenyl)-3-nitro-2,3,4,5-tetrahydro-1H-benzo-
[b][1,4]diazepine (3h). dr 75:25 (a) Major isomer (3h): Yellow 
solid; Yield 98 mg, 65%; mp 166 oC; IR (film, cm-1) 3395 (br m), 
3060 (w), 2917 (w), 1600 (m), 1544 (vs), 1505 (m), 1458 (m), 
1353 (s), 1315 (m), 750 (vs); 1H NMR (CDCl3, 400 MHz) δ 7.51-
6.55 (m, 1H), 7.44-7.48 (m, 1H), 7.28-7.36 (m, 2H), 6.82 (td, J = 
7.4, 1.1 Hz, 1H), 6.77 (td, J = 7.4, 1.1 Hz, 1H), 6.68 (dd, J = 7.4, 
1.1 Hz, 1H), 6.62 (dd, J = 7.4, 1.1 Hz, 1H), 5.73 (d, J = 9.8 Hz, 
1H), 5.22 (ddd, J = 9.8, 4.2, 3.0 Hz, 1H), 4.34 (dd, J = 14.6, 4.2 
Hz, 1H), 3.75 (dd, J = 14.6, 3.0 Hz, 1H), 2 NH protons are not 
observed; 13C NMR (CDCl3, 100 MHz) δ 137.6, 137.4, 136.0, 
134.4, 130.8, 130.2, 128.4, 127.8, 122.0, 121.3, 119.4, 118.9, 
87.8, 58.8, 49.1; HRMS (ES+, Ar) calcd for C15H14ClN3O2Na 
(MNa+) 326.0667, found 326.0668.  
(b) Minor isomer (3h’):  Yellow solid; Yield 32 mg, 21%; mp 
167 oC; IR (film, cm-1) 3394 (br s), 3060 (w), 2916 (w), 1599 
(m), 1544 (vs), 1505 (m), 1459 (m), 1353 (m), 1315 (m), 1253 
(w), 1089 (w), 751 (vs); 1H NMR (CDCl3, 400 MHz) δ 7.41-7.44 
(m, 2H), 7.28-7.36 (m, 2H), 6.90-6.96 (unresolved m, 1H), 6.83-
6.88 (unresolved  m, 2H), 6.73-6.78 (unresolved  m, 1H) 5.66 (d, 
J = 3.9 Hz, 1H), 5.31-5.37 (m, 1H), 4.43 (dd, J = 13.4, 9.4 Hz, 
1H), 3.82 (dd, J = 13.4, 5.5 Hz, 1H), 2 NH protons are not 
observed; 13C NMR (CDCl3, 100 MHz) δ 138.4, 136.5, 135.0, 
132.5, 129.9, 129.8, 128.0, 126.8, 122.2, 121.5, 121.0, 118.8, 
85.9, 57.9, 48.0; HRMS (ES+, Ar) calcd for C15H14ClN3O2Na 
(MNa+) 326.0667, found 326.0659.  
2-(3-Bromophenyl)-3-nitro-2,3,4,5-tetrahydro-1H-benzo-
[b][1,4]diazepine (3i). Yellow solid; Yield 132 mg, 76%, dr 
92:08; Major isomer (minor isomer could not be isolated in pure 
form): mp 191 oC, IR (film, cm-1) 3394 (br s), 3053 (m), 2921 
(w), 1599 (s), 1544 (vs), 1458 (s), 1352 (m), 1314 (s), 1265 (s), 
804 (m), 778 (s), 737 (vs); 1H NMR (CDCl3, 400 MHz) δ 7.62 (t, 
J = 1.6 Hz, 1H), 7.52 (dt, J = 8.1, 1.6 Hz, 1H), 7.38 (d, J = 7.8 
Hz, 1H), 7.29 (t, J = 8.1 Hz, 1H), 6.82 (td, J = 7.6, 1.5 Hz, 1H), 
6.76 (td, J = 7.6, 1.5 Hz, 1H), 6.67 (dd, J = 7.6, 1.5 Hz, 1H), 6.59 
(dd, J = 7.6, 1.5 Hz, 1H), 5.20 (d, J = 9.6 Hz, 1H), 4.90 (ddd, J = 
9.6, 4.3, 2.8 Hz, 1H), 4.34 (dd, J = 14.7, 4.3 Hz, 1H), 3.69 (dd, J 
= 14.7, 2.8 Hz, 1H), 3.29 (br s, 1H), 1 NH proton is not observed; 
13C NMR (CDCl3, 100 MHz) δ 141.2, 137.5, 137.2, 132.5, 131.0, 
130.6, 126.4, 123.4, 122.1, 121.4, 119.4, 119.0, 90.2, 62.0, 49.2; 
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[b][1,4]diazepine (3j). Major + Minor: Yellow solid; 118 mg, 
75%; dr 80:20; Major isomer (minor isomer could notbe isolated 
in pure form): Yellow solid; Yield 95 mg, 60%; mp 169-171 oC; 
IR (film, cm-1) 3390 (br s), 2924 (m), 2853 (w), 1542 (s), 1527 
(s), 1506 (w), 1459 (w), 1354 (m), 1264 (w), 745 (s); 1H NMR 
(CDCl3, 400 MHz) δ 7.61-7.63 (unresolved m, 1H), 7.52 (d, J = 
7.8 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 
6.82 (t, J = 7.6 Hz, 1H), 6.75 (t, J = 7.6 Hz, 1H), 6.67 (d, J = 7.6 
Hz, 1H), 6.60 (d, J = 7.6 Hz, 1H), 5.20 (d, J = 9.6 Hz, 1H), 4.90 
(ddd, J = 9.6, 4.2, 3.6 Hz, 1H), 4.34 (dd, J = 14.6, 4.2 Hz, 1H), 
3.69 (dd, J = 14.6, 3.6 Hz, 1H), 3.28 (br s, 1H), 1 NH proton is 
not observed; 13C NMR (CDCl3, 100 MHz) δ 141.2, 137.5, 137.2, 
132.5, 131.0, 130.6, 126.4, 123.4, 122.1, 121.4, 119.4, 119.0, 
90.3, 62.0, 49.3;  HRMS (ES+, Ar) calcd for C15H14N4O4 (MH
+) 
315.1088, found 315.1087. 
3-Nitro-2-(thiophen-2-yl)-2,3,4,5-tetrahydro-1H-benzo-
[b][1,4]diazepine (3k). Yellow solid; Yield 94 mg, 68%, dr 
94:06; Major isomer (minor isomer could not be isolated in pure 
form): mp 81 oC; IR (film, cm-1) 3388 (br s), 2919 (w), 1599 (m), 
1544 (vs), 1505 (s), 1459 (s), 1354 (m), 1315 (s), 1089 (m), 750 
(s); 1H NMR (CDCl3, 400 MHz) δ 7.33 (dd, J = 5.1, 0.7 Hz, 1H), 
7.12 (dd, J = 3.5, 0.7 Hz, 1H), 7.00 (dd, J = 5.1, 3.5 Hz, 1H), 
6.82 (td, J = 7.5, 1.6 Hz, 1H), 6.76 (td, J = 7.5, 1.6 Hz, 1H), 6.67 
(dd, J = 7.5, 1.6 Hz, 1H), 6.62 (dd, J = 7.5, 1.6 Hz, 1H), 5.59 (d, 
J = 9.6 Hz, 1H), 4.94, 4.91 (ddd, J = 9.5, 4.4, 2.7 Hz, 1H), 4.31 
(dd, J = 14.8, 4.4 Hz, 1H), 3.80 (br s, 1H), 3.68 (dd, J = 14.8, 2.7 
Hz, 1H), 3.43 (br s, 1H); 13C NMR (CDCl3, 100 MHz) δ 141.2, 
137.5, 136.9, 127.3, 126.8, 126.1, 122.1, 121.3, 119.5, 119.0, 
91.3, 57.7, 49.1; HRMS (ES+, Ar) calcd for C13H13N3O2SNa 
(MNa+) 298.0621, found 298.0617. 
4-(Furan-2-yl)-7/8-methyl-3-nitro-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepine (4ab + 5ab). Yellow semi-solid, Yield 
114 mg, 84% (1:1 ratio, inseparable, dr >95:5); IR (film, cm-1) 
3391 (br s), 3053 (w), 2920 (w), 2920 (m), 1599 (s), 1543 (vs), 
1506 (s), 1459 (s), 1353 (m), 1315 (s), 1281 (m), 1253 (s), 1086 
(w), 1031 (w), 778 (m), 747 (s);  1H NMR (CDCl3, 400 MHz) δ 
7.42-7.44 (unresolved m, 1H), 6.59, 6.57 (ABqd, J = 8.2, 0.9 Hz, 
1H), 6.55, 6.52 (ABq, J = 7.7 Hz, 1H), 6.43-6.45 (unresolved m, 
1H), 6.35-6.37 (m, 1H), 6.32-6.34 (m, 1H), 5.50 (d, J = 9.4 Hz, 
0.5H), 5.45 (d, J = 9.4 Hz, 0.5H), 5.06 (ddd, J = 9.4, 4.4, 2.0 Hz, 
0.5H), 5.03 (ddd, J = 9.4, 4.4, 2.0 Hz, 0.5H), 4.26 (dd, J = 15.0, 
4.4 Hz, 0.5H), 4.22 (dd, J = 15.0, 4.4 Hz, 0.5H), 3.72 (dt, J = 
15.0, 2.0 Hz, 1H), 3.45 (br s, 2H), 2.22 (s, 1.5H), 2.20 (s, 1.5H); 
13C NMR (CDCl3, 100 MHz) δ 151.1, 151.0, 143.1, 143.0, 137.3, 
136.6, 134.8, 134.2, 131.4, 130.7, 122.3, 121.6, 119.7, 119.2, 
119.1, 118.8, 110.8, 110.7, 108.6, 108.5, 87.4, 55.6, 5.3, 48.8, 
48.5, 20.6, 20.5; HRMS (ES+, Ar) calcd for C14H15N3O3Na 
(MNa+) 296.1006, found 296.1002. 
7/8-Chloro-4-(furan-2-yl)-3-nitro-2,3,4,5-tetrahydro-1H-
benzo[b][1,4]diazepine (4ac + 5ac). Yellow semi-solid, Yield 
111 mg, 76% (1:1 ratio, inseparable, dr >95:5); IR (film, cm-1) 
3398 (br s), 3124 (m), 2921 (m), 2855 (w), 1597 (m), 1551 (s), 
1499 (m), 1352 (m), 1310 (s), 1284 (m), 1086 (m), 807 (s), 745 
(vs); 1H NMR (CDCl3, 400 MHz) δ 7.43 (d, J = 0.7 Hz, 1H), 6.72 
(dd, J = 8.3, 2.2 Hz, 0.5H), 6.67 (dd, J = 8.3, 2.2 Hz, 0.5H), 6.59 
(d, J = 2.2 Hz, 1H), 6.53 (d, J = 8.3 Hz, 0.5H), 6.50 (d, J = 8.3 
Hz, 0.5H), 6.35-6.37 (m, 1H), 6.32-6.34 (m, 1H), 5.53 (d, J = 9.2 
Hz, 0.5H), 5.48 (d, J = 9.2 Hz, 0.5H), 5.05 (ddd, J = 9.2, 4.2, 2.7 
Hz, 0.5H), 5.02 (ddd, J = 9.2, 4.2, 2.7 Hz, 0.5H), 4.30 (td, J = 
14.8, 4.2 Hz, 1H), 3.76 (dd, J = 14.8, 2.7 Hz, 1H), 3.51 (br s, 
1H); 13C NMR (CDCl3, 100 MHz) δ 150.6, 150.4, 143.3, 143.2, 
138.3, 137.5, 135.9, 135.2, 126.3, 125.4, 121.3, 120.6, 119.9, 
119.4, 118.6, 118.1, 110.8, 110.8, 108.8, 108.7, 86.8, 86.7, 55.2, 
55.0, 48.3, 48.0; HRMS (ES+, Ar) calcd for C13H12ClN3O3Na 
(MNa+) 316.0459, found 316.0457.  
4-(2-Chlorophenyl)-3-nitro-1-phenyl-2,3,4,5-tetrahydro-
1H-benzo[b][1,4]diazepine (6h).  Yellow solid; Yield 136 mg, 
72%, dr 88:12 (minor isomer could not be isolated in pure form); 
Major isomer: mp 166 oC; IR (film, cm-1) 3392 (br w), 3059 (w), 
2925 (vw), 1592 (m), 1578 (w), 1546 (s), 1499 (m), 1475 (w), 
1358 (w), 1298 (w), 752 (vs); 1H NMR (CDCl3, 400 MHz) δ 
7.54-7.65 (m, 2H), 7.35-7.45 (m, 4H), 7.18-7.26 (m, 2H), 7.03-
7.10 (m, 3H), 6.70-7.02 (m, 2H), 5.62 (d, J = 10.0 Hz, 1H), 5.40 
(ddd, J = 10.0, 5.8, 4.1 Hz, 1H), 4.83 (dd, J = 15.4, 4.1 Hz, 1H), 
4.54 (dd, J = 15.4, 5.8 Hz, 1H), 3.49 (br s, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 147.2, 143.8, 136.2, 135.7, 134.5, 130.7, 
130.3, 129.7, 128.0, 127.8, 127.7, 126.3, 122.7, 121.1, 120.3, 
117.0, 85.8, 58.6, 52.5; HRMS (ES+, Ar) calcd for C21H19N3O2Cl 
(MH+) 380.1160, found 380.1155. 
 (E)-N1-(3-(Furan-2-yl)-2-nitroallyl)-N 2-phenylbenzene-1,2-
diamine (7a). Yellow solid; Yield 143 mg, 85%; mp 152 oC; IR 
(film, cm-1) 3374 (br m), 3047 (w), 1597 (s), 1509 (s), 1500 (s), 
1308 (vs), 1022 (w), 930 (w), 748 (vs); 1H NMR (CDCl3, 400 
MHz) δ 7.88 (s, 1H), 7.53-7.55 (unresolved m, 1H), 7.13-7.21 
(m, 3H); 6.98-7.03 (m, 1H), 6.88-6.94 (m, 2H), 6.76-6.84 (m, 
2H), 6.69-6.73 (m, 2H), 6.57 (dd, J = 3.5, 1.8 Hz, 1H), 4.81 (s, 
2H), 2 NH protons are not observed; 13C NMR (CDCl3, 100 
MHz) δ 147.4, 147.2, 145.6, 145.1, 142.6, 129.8, 129.4, 125.8, 
124.7, 122.8, 121.8, 119.5, 119.0, 115.5, 113.4, 113.1, 40.6; 
HRMS (ES+, Ar) calcd for C19H18N3O3 (MH
+) 336.1348, found 
336.1334. 
(E)-N1-(2-Nitro-3-p-tolylallyl)-N 2-phenylbenzene-1,2-
diamine (7c). Yellow solid; Yield 133 mg, 74%; mp 142 oC; IR 
(film, cm-1)  3378 (br s), 3048 (w), 2921 (w), 1644 (w), 1601 (s), 
1545 (w), 1498 (s), 1312 (w), 1279 (w), 819 (w), 747 (s); 1H 
NMR (CDCl3, 400 MHz) δ 8.19 (s, 1H), 7.37 (d, J = 8.0 Hz, 2H), 
7.26 (d, J = 8.0 Hz, 2H), 7.14-7.22 (m, 3H), 7.03 (td, J = 7.6, 1.0 
Hz, 1H), 6.84 (td, J = 7.6, 1.0 Hz, 1H), 6.78 (dd, J = 7.6, 1.0 Hz, 
1H), 6.71-6.76 (m, 2H), 6.55 (dd, J = 7.6, 1.0 Hz, 1H), 5.00-5.15 
(br s, 1H), 4.45 (s, 2H), 2.4 (s, 3H), 1 NH proton is not observed; 
13C NMR (CDCl3, 100 MHz) δ 147.5, 145.4, 142.2, 141.7, 137.6, 
130.3, 130.1, 129.4, 128.8, 125.7, 124.4, 119.8, 119.2, 115.9, 
112.6, 40.8, 21.7; HRMS (ES+, Ar) calcd for C22H22N3O2 (MH
+) 
360.1712, found 360.1696. 
(E)-N1-(3-(4-Methoxyphenyl)-2-nitroallyl)-N2-phenyl-
benzene-1,2-diamine (7d). Yellow solid; Yield 95 mg, 85%; mp 
120 oC; IR (film, cm-1) 3365 (br m), 2927 (w), 1603 (vs), 1545 
(m), 1512 (vs), 1305 (m), 1257 (vs), 1178 (s), 1028 (m), 749 (s); 
1H NMR (CDCl3, 400 MHz) δ 8.19 (s, 1H), 7.45 (d, J = 8.8 Hz, 
2H), 7.19 (overlapped t, J = 8.4 Hz, 2H), 7.18 (overlapped t, J = 
8.0 Hz, 1H), 7.05 (t, J = 8.4 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 
6.82 (t, J = 8.0 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.74 (d, J = 8.4 
Hz, 2H), 6.62 (d, J = 8.0 Hz, 1H), 5.14 (br s, 1H), 4.54 (br s, 1H), 
4.45 (s, 2H), 3.86 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 162.1, 
146.1, 145.4, 142.4, 137.7, 132.5, 130.1, 129.4, 125.8, 124.3, 
124.0, 119.8, 119.2, 115.9, 114.9, 112.5, 55.6, 41.0; HRMS (ES+, 
Ar) calcd for C22H22N3O3 (MH
+) 376.1656, found 376.1654. 
(E)-N1-(3-(Benzo[d][1,3]dioxol-5-yl)-2-nitroallyl)-N2-
phenylbenzene-1,2-diamine (7f). Yellow solid; Yield 152 mg, 
78%; mp 150 oC; IR (film, cm-1) 3380 (br w), 3060 (vw), 2913 
(w), 1643 (w), 1598 (s), 1501 (vs), 1310 (m), 1247 (s), 1037 (s), 
747 (vs); 1H NMR (CDCl3, 400 MHz) δ 8.14 (s, 1H), 7.15-7.19 
(m, 3H), 7.01-7.08 (m, 3H), 6.77-6.89 (m, 3H), 6.74 (d, J = 7.7 
Hz, 2H), 6.62 (d, J = 8.0 Hz, 1H), 6.04 (s, 2H), 5.15 (br s, 1H), 
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4.42 (s, 2H), 1 NH proton is not observed; 13C NMR (CDCl3, 100 
MHz) δ 150.3, 148.7, 146.5, 145.4, 142.3, 137.7, 130.1, 129.4, 
126.4, 125.8, 125.5, 124.4, 119.8, 119.3, 115.9, 112.5, 109.8, 
109.2, 102.1, 41.0; HRMS (ES+, Ar) calcd for C22H20N3O4 (MH
+) 
390.1454, found 390.1464. 
(E)-N1-(3-(4-Chlorophenyl)-2-nitroallyl)-N 2-phenyl-
benzene-1,2-diamine (7g). Dark yellow solid; Yield 80 mg, 
70%; mp 139 oC; IR (film, cm-1) 3374 (br m), 3053 (w), 2927 
(w), 1595 (s), 1546 (m), 1496 (vs), 1319 (s), 1092 (m), 749 (vs); 
1H NMR (CDCl3, 500 MHz) δ 8.14 (s, 1H), 7.42, 7.38 (ABq, J =  
8.5 Hz, 4H), 7.20 (t, J = 7.8 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 
7.02 (t, J = 7.8 Hz, 1H), 6.84 (t, J = 8.0 Hz, 1H), 6.79 (t, J = 8.0 
Hz, 1H), 6.72 (d, J = 7.8 Hz, 2H), 6.53 (d, J = 8.0 Hz, 1H), 5.14 
(br s, 1H), 4.56 (br s, 1H), 4.40 (d, J = 4.0 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz) δ 148.6, 145.3, 142.0, 137.2, 136.0, 131.4, 
130.2, 130.1, 129.7, 129.4, 125.8, 124.5, 119.9, 119.5, 115.9, 
112.7, 40.8; HRMS (ES+, Ar) calcd for C21H19ClN3O2 (MH
+) 
380.1160, found 380.1164. 
(E)-N1-(2-Nitro-3-(2-nitrophenyl)allyl)-N 2-phenylbenzene-
1,2-diamine (7j). Yellow solid; Yield 83 mg, 71%; mp 155 oC; 
IR (film, cm-1) 3373 (br m), 2922 (m), 2853 (w), 1597 (m), 1524 
(vs), 1497 (m), 1343 (m), 749 (m); 1H NMR (CDCl3, 400 MHz) δ 
8.46 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 8.0 Hz, 2H), 
7.36 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 2H), 7.10 (d, J = 8.0 
Hz, 1H), 6.92 (t, J = 7.6 Hz, 1H), 6.84 (t, J = 8.0 Hz, 1H), 6.75 (t, 
J = 8.0 Hz, 1H), 6.68 (d, J = 7.6 Hz, 2H), 6.38 (d, J = 8.0 Hz, 
1H),  5.15 (s, 1H), 4.51 (br s, 1H), 4.25 (d, J = 5.2 Hz, 2H); 13C 
NMR (CDCl3, 100 MHz) δ 149.1, 147.3, 145.2, 141.5, 134.4, 
134.3, 131.0 (× 2), 130.4, 129.4, 128.0, 125.6, 125.4, 124.2, 
119.9, 115.8 (× 2), 113.3, 40.8; HRMS (ES+, Ar) calcd for 
C21H18KN4O4 (MK
+) 429.0960, found 429.0958. 
(E)-N1-(2-Nitro-3-(3,4,5-trimethoxyphenyl)allyl)-N2-
phenylbenzene-1,2-diamine (7l). Red solid; Yield 105 mg, 81%; 
mp 130 oC; IR (film, cm-1) 3358 (br m), 2936 (m), 1593 (s), 1547 
(m), 1498 (s), 1463 (m), 1420 (m), 1316 (m), 1240 (m), 1128 
(vs), 1004 (m), 748 (s); 1H NMR (CDCl3, 400 MHz) δ 8.16 (s, 
1H), 7.19 (t, J = 8.0 Hz, 2H), 7.16 (t, J = 7.6 Hz, 1H), 7.04 (t, J = 
8.0 Hz, 1H), 6.83 (t, J = 7.6 Hz, 1H), 6.80 (d, J = 7.6 Hz, 1H), 
6.76 (s, 2H), 6.74 (d, J = 8.0 Hz, 2H), 6.65 (d, J = 7.6 Hz, 1H), 
5.17 (br s, 1H), 4.60 (br s, 1H), 4.43 (d, J = 4.8 Hz, 2H), 3.90 (s, 
3H), 3.71 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 153.6, 147.2, 
145.3, 142.1, 140.6, 137.9, 130.0, 129.4, 126.9, 125.6, 124.1, 
119.9, 119.3, 115.8, 112.2, 107.6, 61.1, 56.1, 41.2; HRMS (ES+, 
Ar) calcd for C24H26N3O5 (MH
+) 436.1867, found 436.1875. 
(E)-N1-(3-(Naphthalen-1-yl)-2-nitroallyl)-N2-phenyl-
benzene-1,2-diamine (7m). Brown solid; Yield 85 mg, 72%; mp 
159 oC; IR (film, cm-1) 3375 (br m), 3048 (w), 1652 (w), 1596 
(s), 1521 (vs), 1445 (m), 1330 (s), 1266 (m), 748 (vs); 1H NMR 
(CDCl3, 500 MHz) δ 8.73 (s, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.95 
(d, J = 7.5 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.56-7.64 (m, 2H), 
7.51 (t, J = 7.5 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.19 (t, J = 7.9 
Hz, 2H), 7.05 (d, J = 7.3 Hz, 1H), 6.83 (t, J = 7.3 Hz, 1H), 6.63-
6.70 (m, 4H), 6.21 (d, J = 7.3 Hz, 1H), 5.0 (br s, 1H), 4.67 (br s, 
1H), 4.44 (s, 2H); 13C NMR (CDCl3, 126 MHz) δ 149.8, 145.5, 
142.0, 135.3, 133.6, 131.5, 131.1, 129.6, 129.4, 129.0 (× 2), 
127.6, 127.5, 127.0, 125.8, 125.5, 124.8, 124.5, 119.7, 119.0, 
115.6, 112.5, 40.5; HRMS (ES+, Ar) calcd for C25H22N3O2 (MH
+) 
396.1707, found 396.1702. 
(E)-N1-(3-(2,5-Dimethoxyphenyl)-2-nitroallyl)-N2-
phenylbenzene-1,2-diamine (7n). Yellow solid; Yield 103 mg, 
85%; mp 151-153 oC; IR (film, cm-1) 3367 (br vs), 3044 (vw), 
2942 (w), 2835 (w), 1595 (s), 1543 (w), 1496 (vs), 1461 (m), 
1418 (w), 1301 (s), 1025 (vs), 745 (vs); 1H NMR (CDCl3, 400 
MHz) δ 8.36 (s, 1H), 7.19 (t, J = 7.6 Hz, 2H), 7.13 (d, J = 8.3 
Hz, 1H), 6.94-7.02 (m, 3H), 6.88 (d, J = 8.3 Hz, 1H), 6.82 (t, J = 
7.8 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.71 (d, J = 7.6 Hz, 2H), 
6.55 (d, J = 7.8 Hz, 1H), 5.11 (br s, 1H), 4.61 (t, J = 6.0 Hz, 1H), 
4.39 (d, J = 6.0 Hz, 2H), 3.81 (s, 3H), 3.61 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 153.6, 152.7, 148.0, 145.5, 142.3, 133.5, 
129.9, 129.4, 125.7, 124.3, 121.3, 119.8, 119.1, 118.4, 115.8, 
114.9, 112.5, 112.3, 56.3, 55.7, 41.1; HRMS (ES+, Ar) calcd for 
C23H23N3O4Na (MNa
+) 428.1581, found 428.1581. 
(S)-1-(Bis((E)-3-(furan-2-yl)-2-nitroallyl)amino)-3-phenyl-
propan-2-ol (8). The starting materials 1a and 2e were used in 
2:1 ratio); Yellow solid, Yield 98 mg, 72%; mp 164 oC; IR (film, 
cm-1) 3512 (br w), 3148 (br w), 3121 (br w), 2926 (w), 1649 (m), 
1512 (s), 1312 (vs), 1023 (m), 753 (m); 1H NMR (CDCl3, 400 
MHz) δ 7.99 (s, 2H), 7.67 (unresolved m, 2H), 7.13-7.22 (m, 
2H), 6.93-6.96 (m, 4H), 6.60 (ABq, J = 1.7 Hz, 2H), 4.41 (d, J = 
13.9 Hz, 2H), 4.14 (d, J = 13.9 Hz, 2H), 3.63 (t, J = 11.0 Hz, 
1H), 3.28-3.34 (m, 2H), 2.99-3.05 (m, 1H), 2.60 (br s, 1H), 2.48-
2.58 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 147.4, 147.2, 144.4, 
138.4, 129.0, 128.7, 126.4, 123.9, 122.4, 113.5, 63.0, 60.2, 45.1, 
31.5; HRMS (ES+, Ar) calcd for C23H24N3O7 (MH
+) 454.1609, 
found 454.1611. 
General procedure for the reaction of MBH-acetate 1 and 
10 with aminoamide 2f. To a stirred solution of MBH acetate 
1/10 (0.3 mmol) in methanol (1.5 mL) at room temperature was 
added 2f (0.3 mmol). The reaction mixture was stirred till 
complete consumption of the starting materials (monitored by 
TLC). The solvent was evaporated in vacuo and the crude residue 
was purified by silica gel column chromatography (20-40% EA / 
pet ether). 
(E)-2-(3-(4-Methoxyphenyl)-2-nitroallylamino)benzamide 
(9d). Yellow solid; Yield 88 mg, 90%; mp 171 oC; IR (film, cm-
1)  3467 (br w), 3320 (br m), 1646 (s), 1603 (s), 1510 (s), 1305 
(s), 1453 (w), 1384 (w), 1305 (s), 1256 (vs), 1177 (s), 1027 (m), 
834 (m), 742 (m); 1H NMR (CDCl3, 400 MHz) δ 8.26 (s, 1H), 
7.45 (d, J = 8.7 Hz, 2H), 7.41 (dd, J = 8.1, 1.4 Hz, 1H), 7.31 (td, 
J = 8.1, 1.4 Hz, 1H), 6.95 (d, J = 8.7 Hz, 2H), 6.67 (td, J = 8.1, 
1.4 Hz, 1H), 6.61 (dd, J = 8.1, 1.4 Hz, 1H), 5.7 (br s, 1H), 4.52 
(s, 2H), 3.85 (s, 3H), 2 NH protons are not observed; 13C NMR 
(CDCl3, 100 MHz) δ 171.9, 162.1, 149.4, 145.8, 137.8, 133.7, 
132.5, 128.6, 123.9, 116.0, 115.0, 114.4, 112.3, 55.6, 40.0; 




(9g). Yellow solid; Yield 82 mg, 82%; mp 172 oC; IR (film, cm-1) 
3266 (br m), 2930 (w), 2861 (w), 1645 (m), 1578 (m), 1488 (m), 
1396 (s), 1318 (vs), 1287 (vs), 1087 (m), 752 (vs); 1H NMR 
(CDCl3, 400 MHz) δ  8.50 (t, J = 5.6 Hz, 1H), 8.28 (s, 1H), 7.87 
(br s, 1H), 765, 7.60 (ABq, J = 8.7 Hz, 4H), 7.64 (overlapped d, J 
= 7.8 Hz, 1H), 7.21 (br s, 1H), 7.18 (t, J = 7.8 Hz, 1H), 6.60 (t, J
= 7.8 Hz, 1H), 6.42 (d, J = 7.8 Hz, 1H), 4.45 (d, J = 5.6 Hz, 2H); 
13C NMR (CDCl3, 100 MHz) δ 171.3, 148.6 (× 2), 135.6, 135.2, 
132.5, 131.9, 130.2, 129.2, 129.1, 115.3, 115.0, 111.4, 79.1; 




Yellow solid; Yield 86 mg, 84%; mp 166 oC; IR (film, cm-1) 
3477 (br w), 3348 (br m), 2974 (w), 2925 (w), 1656 (s), 1615 
(m), 1523 (vs), 1344 (s), 1095 (w), 753 (s); 1H NMR (CDCl3, 400 
MHz) δ 8.49 (s, 1H), 8.21 (dd, J = 8.1, 1.0 Hz, 1H), 7.67 (td, J = 
8.1, 1.0 Hz, 1H), 7.58 (td, J = 8.1, 0.8 Hz, 1H), 7.44 (d, J = 7.6 
Hz, 1H), 7.30 (dd, J = 7.6, 1.4 Hz, 1H), 7.17 (td, J = 7.6, 1.4 Hz, 
1H), 6.61 (t, J = 7.6 Hz, 1H), 6.36 (dd, J = 8.1, 0.8 Hz, 1H), 5.90 
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(br s, 2H), 4.39 (s, 2H), 1 NH proton is not observed; 13C NMR 
(CDCl3, 100 MHz) δ 171.8, 148.6, 148.5, 146.8, 134.4, 133.5, 
130.9, 130.8, 128.5, 128.1, 125.4, 116.4, 114.3, 112.0, 39.8; 




benzamide (9l). Light yellow solid; Yield 93 mg, 80%; mp 169 
oC; IR (film, cm-1)  3415 (s), 3298 (m), 3170 (s), 3055 (m), 1672 
(m), 1651 (m), 1621 (s), 1579 (m), 1504 (s), 1452 (m), 1392 (s), 
1316 (vs), 1265 (vs), 1231 (m), 1156 (m), 990 (s); 1H NMR 
(CDCl3, 500 MHz) δ 8.23 (s, 1H), 8.17 (t, J = 4.5 Hz, 1H), 7.40 
(d, J = 7.5 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 6.77 (s, 2H), 6.67 (t, 
J = 7.5 Hz, 1H), 6.65 (d, J = 7.5 Hz, 1H), 5.89 (br s, 2H), 4.47 (d, 
J = 4.5 Hz, 2H), 3.87 (s, 3H), 3.68 (s, 6H); 13C NMR (CDCl3, 125 
MHz) δ 171.9, 153.6, 149.2, 146.9, 140.5, 138.4, 133.8, 12 .6, 
126.9, 116.2, 114.4, 112.1, 107.6, 61.1, 56.1, 40.3; HRMS (ES+, 
Ar) calcd for C19H21N3NaO6 (MNa
+) 410.1323, found 410.1313. 
(E)-2-((3-(Naphthalen-1-yl)-2-nitroallyl)amino)benzamide 
(9m). Yellow solid; Yield 81 mg, 77%; mp 171 oC; IR (film, cm-
1) 3313 (br m), 3186 (m), 1676 (m), 1648 (m), 1613 (m), 1571 
(m), 1511 (m), 1385 (s), 1322 (vs), 1280 (s), 1254 (m), 750 (s), 
733 (s), 524; 1H NMR (CDCl3, 500 MHz) δ 8.75 (s, 1H), 8.22 (t, 
J = 6.1 Hz, 1H), 7.96-7.80 (m, 1H), 7.92-7.96 (m, 1H), 7.85-7.89 
(m, 1H), 7.55-7.61 (m, 2H), 7.51-7.54 (m, 2H), 7.32 (d, J = 8.0 
Hz, 1H), 6.85 (t, J = 8.0 Hz, 1H), 6.52 (t, J = 8.0 Hz, 1H), 6.15 
(d, J = 8.0 Hz, 1H), 5.69 (br s, 2H), 4.50 (d, J = 6.1 Hz, 2H); 13C 
NMR (CDCl3, 125 MHz) δ 171.8, 149.7, 148.9, 135.1, 133.6, 
133.4, 131.6, 131.1, 129.0, 128.5, 127.7, 127.5, 127.0, 125.5, 
124.5, 115.8, 114.3, 112.2, 39.5; HRMS (ES+, Ar) calcd for 
C20H18N3O3 (MH
+) 348.1343, found 348.1348. 
(E)-Ethyl 2-(2-carbamoylphenylamino)-4-(4-methoxy-
phenyl)-3-nitrobut-3-enoate (11a). Yellow solid, 102 mg, 85%; 
mp 161 oC;  IR (film, cm-1) 3055 (w), 2926 (m), 2851 (w), 1754 
(s), 1659 (s), 1606 (s), 1579 (m), 1513 (s), 1372 (w), 1265 (s), 
1178 (s), 1027 (s), 739 (vs), 704 (s); 1H NMR (CDCl3, 400 MHz) 
δ 8.24 (s, 1H), 7.53 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 7.7 Hz, 1H), 
7.02 (d, J = 8.4 Hz, 2H), 7.00-7.05 (m, 1H), 6.59 (t, J = 7.7 Hz, 
1H), 6.06 (brs, 1H), 5.91 (d, J = 7.7 Hz, 1H), 5.53 (s, 1H), 4.33 
(q, J = 6.9 Hz, 2H), 3.89 (s, 3H), 1.31 (t, J = 6.9 Hz, 3H), 2 NH 
protons are not observed; 13C NMR (CDCl3, 100 MHz) δ 171.8, 
171.7, 169.1, 162.0, 147.4, 146.4, 137.1, 133.2, 131.8, 128.9, 
123.5, 116.5, 115.5, 115.0, 112.1, 62.8, 55.7, 53.4; HRMS (ES+, 
Ar) calcd for C20H21N3O6Na (MNa
+) 422.1323, found 422.1325. 
 (Z)-Ethyl 4-((2-carbamoylphenyl)amino)-4-(naphthalen-1-
yl)-3-nitrobut-2-enoate (11b). Yellow solid; Yield 108 mg, 
85%; mp 196 oC; IR (film, cm-1) 3588 (br vs), 3007 (w), 2944 
(w), 1637 (m), 1443 (m), 1376 (m), 1040 (m); 1H NMR (CDCl3, 
500 MHz) δ 8.82 (s, 1H), 8.78 (d, J = 7.6 Hz, 1H), 8.03 (d, J = 
8.0 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 
7.76 (d, J = 7.2 Hz, 1H), 7.53-7.66 (m, 3H), 7.32-7.28 (m, 1H), 
6.48-6.44 (m, 2H), 5.75 (br s, 2H), 5.62-5.58 (m, 1H), 5.48 (d, J 
= 7.6 Hz, 1H), 4.47, 4.32 (ABqd, J = 10.6, 7.0 Hz, 2H), 1.38 (t, J 
= 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.4, 168.8, 
149.0, 147.1, 135.8, 133.6, 133.0, 131.5 (× 2), 129.0, 128.6 (× 2), 
127.7, 127.6, 127.2, 125.6, 124.6, 116.4, 115.4, 112.2, 63.0, 53.7, 
14.3; HRMS (ES+, Ar) calcd for C23H22N3O5 (MH
+) 420.1554, 
found 420.1550. 
Procedure for the reaction of MBH acetate 12 with amine 2a.  
To a stirred solution of MBH acetate 12 (0.5 mmol) in 
methanol (5 mL) at room temperature was added amino 
compound 2a (0.5 mmol). The reaction mixture was stirred till 
complete consumption of the starting materials (monitored by 
TLC). The solvent was evaporated in vacuo and the crude residue 
was purified by silica gel column chromatography (10-20% EA / 
pet ether). 
Ethyl 2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepine-3-
carboxylate (13). Colorless liquid; Yield 39 mg, 35%; IR (film, 
cm-1) 3376 (br s), 2978 (w), 2925 (m), 2855 (w), 1721 (vs), 1648 
(m), 1598 (m), 1507 (s), 1315 (s), 749 (s); 1H NMR (CDCl3, 400 
MHz) δ 6.73 (d, J = 3.6 Hz, 1H), 6.71 (t, J = 3.6 Hz, 1H), 6.66 (t, 
J = 3.6 Hz, 1H), 6.64 (d, J = 3.6 Hz, 1H), 4.17 (q, J = 7.1 Hz, 
2H), 3.57 (dd, J = 13.1, 4.5 Hz, 2H), 3.40 (dd, J = 13.1, 7.5 Hz, 
2H), 2.83 (tt, J = 7.5, 4.5 Hz, 1H), 1.27 (d, J = 7.1 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 173.1, 139.8, 121.2, 119.4, 60.8, 
47.9, 47.0, 14.4; HRMS (ES+, Ar) calcd for C12H16N2O2K (MK
+) 
259.0843, found 259.0847. 
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 Nitrobenzodiazepines have been synthesized from nitroallylic acetates for the first 
time  
 
 The Nitroallylic acetates react as 1,3-bielectrophiles with 1,4-binucleophilic o-
phenylenediamines in a [4+3] fashion 
 
  The first step in the reaction of primary nitroallylic acetates has been confirmed to 
be SN2 by isolating the intermediates 
 
 The cascade reaction is highly stereoselective and takes place in MeOH at room 
temperature in the absence of any base or catalyst  
 
 The intermediate SN2 products, N-nitroallylated compounds, possess multiple 
functionalities   
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